drugs

HRSA is piloting a 340B rebate model similar to one that it just fought against. As the agency dips its...

In a recent analysis of HRSA data, the American Hospital Association has turned the tables on drug companies and accused...

A widely panned proposal to regulate virtual prescriptions for controlled drugs isn?t going anywhere. It?s time to bring federal regulators...

Hospitals and health systems must strategically manage rising GLP-1 costs while balancing workforce health and long-term financial sustainability.

CMS suggests a modest 2.4% payment update in the 2026 Hospital Outpatient Prospective Payment System proposed rule on top of...

Drug companies are more likely than hospitals to violate 340B regulations, according to a recent American Hospital Association report.

Hospital price transparency compliance enforcement is set to rise.

Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy (R-Louisiana) recently released the results of an investigation into the...

A recent Executive Order takes aim at drug pricing, with significant implications for the 340B Drug Pricing Program.

A Cedars-Sinai program attaches a substance abuse treatment doctor and social worker to the patient?s care team, improving treatment adherence...

From tariffs, to Medicaid, to PBMs, here?s what to know.

"Proactive not reactive" cost containment strategies are vital for finance executives.